The use of a new semi-quantitative rapid test for procalcitonin in the diagnosis of multisegmental community-acquired pneumonia

被引:0
作者
Bayramova, Sabina S. [1 ]
Nikolayev, Konstantin Yu [1 ]
Tsygankova, Oksana, V [1 ,2 ]
机构
[1] Russian Acad Sci, Inst Internal & Prevent Med, Fed Res Ctr, Inst Cytol & Genet,Siberian Branch, Novosibirsk, Russia
[2] Novosibirsk State Med Univ, Novosibirsk, Russia
关键词
multisegmental community-acquired pneumonia; diagnosis; procalcitonin; biomarkers; prognosis;
D O I
10.26442/00403660.2021.03.200654
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim. Evaluation of the possibilities of a new semi-quantitative rapid test for procalcitonin in the diagnosis of multisegmental community-acquired pneumonia. Materials and methods. A one-stage comparative study involved 123 patients hospitalized in a hospital with a confirmed diagnosis of community-acquired pneumonia. The mean age of the patients was 49.5 +/- 21.0 (M +/- SD) years. On the first day of hospitalization, all patients underwent a general clinical examination, chest x-ray, and a plasma procalcitonin level was determined using a semi-quantitative rapid test. Results. Indicators of a new semi-quantitative rapid test for procalcitonin of at least 2 ng/ml are directly related to laboratory and instrumental indicators reflecting the severity of community-acquired pneumonia, namely, the severity of respiratory failure (p=0.001), respiratory rate (p=0.001), and heart rate contractions (p=0.001), systolic blood pressure (p=0.025), oxygen saturation (p=0,001), erythrocyte sedimentation rate (p=0.021), fibrinogen (p=0.003) and high CRB-65 scores (p=0.001). They are also associated with multisegmental community-acquired pneumonia (chi(2)=4.7; p=0.030) and complications of this disease, such as hydrothorax (p=0.029) and death (chi(2)=22.1; p=0.001). Conclusion. Using a new semi-quantitative rapid test for procalcitonin allows you to optimize the diagnosis of complications of community-acquired pneumonia and determine the high risk of multisegmental pneumonia.
引用
收藏
页码:279 / 282
页数:4
相关论文
共 16 条
  • [1] Chuchalin A.G., 2017, RESP MED GUIDE, V2
  • [2] Chuchalin A.G., 2009, PULMONOLOGY NATL GUI
  • [3] Procalcitonin
    Davies, Julie
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2015, 68 (09) : 675 - 679
  • [4] Qualitative study to explore the views of general practice staff on the use of point-of-care C reactive protein testing for the management of lower respiratory tract infections in routine general practice in England
    Eley, Charlotte Victoria
    Sharma, Anita
    Lecky, Donna Marie
    Lee, Hazel
    McNulty, Cliodna Ann Miriam
    [J]. BMJ OPEN, 2018, 8 (10):
  • [5] Eliseev AO, 2019, B BASHKIR STATE MEDI, V1, P38
  • [6] The past decade in bench research into pulmonary infectious diseases: What do clinicians need to know?
    Finch, Simon
    Keir, Holly R.
    Dicker, Alison J.
    Chalmers, James D.
    [J]. RESPIROLOGY, 2017, 22 (06) : 1062 - 1072
  • [7] Severe community-acquired pneumonia: current management and future therapeutic alternatives
    Garnacho-Montero, Jose
    Barrero-Garcia, Irene
    de Gracia Gomez-Prieto, Maria
    Martin-Loeches, Ignacio
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2018, 16 (09) : 667 - 677
  • [8] Kochegarova EYu, 2011, **DROPPED REF**, V40, P48
  • [9] Kolosov VP, 2012, CLIN COURSE
  • [10] Impact of bacterial and viral coinfection in community-acquired pneumonia in adults
    Lim, Yong Kwan
    Kweon, Oh Joo
    Kim, Hye Ryoun
    Kim, Tae-Hyoung
    Lee, Mi-Kyung
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2019, 94 (01) : 50 - 54